Australia markets open in 5 hours 40 minutes

Navidea Biopharmaceuticals, Inc. (NO1A.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.06650.0000 (0.00%)
As of 09:33AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 4.19M
Enterprise value -381.55k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)310.17
Price/book (mrq)N/A
Enterprise value/revenue -46.95
Enterprise value/EBITDA 0.03

Trading information

Stock price history

Beta (5Y monthly) 0.74
52-week change 3-67.40%
S&P500 52-week change 324.60%
52-week high 30.3020
52-week low 30.0320
50-day moving average 30.0582
200-day moving average 30.1347

Share statistics

Avg vol (3-month) 3560
Avg vol (10-day) 355
Shares outstanding 5100.08M
Implied shares outstanding 6100.08M
Float 864.07M
% held by insiders 135.89%
% held by institutions 10.00%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,678,791.02%

Management effectiveness

Return on assets (ttm)-107.05%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)610
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -10.13M
Net income avi to common (ttm)-8.81M
Diluted EPS (ttm)-0.4200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.86M
Total cash per share (mrq)0.04
Total debt (mrq)1.26M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.56
Book value per share (mrq)-0.03

Cash flow statement

Operating cash flow (ttm)-9.71M
Levered free cash flow (ttm)-7.77M